By Mette Fraende COPENHAGEN (Reuters) – U.S. regulators refused to approve Novo Nordisk’s new long-acting insulin Tresiba until it conducts extra tests for potential heart risks, dealing a major blow to a key product for the Danish drugmaker. Shares in Novo, the world’s...
Novo Nordisk hit hard as U.S. rebuffs insulin drug
Monday, February 11, 2013
Novo Nordisk hit hard as U.S. rebuffs insulin drug
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment